All In MedTech

Device Trial Radar · NCT03087617

Personalized Smoking Cessation Tool Based on Patient Lung CT Image

Last checked: Nov 19, 2026Latest source record: Oct 5, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 321 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

321

Actual

Start

Oct 3, 2018

Primary completion

Feb 21, 2021

Study completion Aug 23, 2021

Sponsor

Lead sponsor
ImbioNot on our public-company list
Sponsor type
Industry
Collaborators
National Cancer Institute (NCI); University of Michigan; Mayo Clinic; HealthPartners Institute; University of Minnesota
First posted
Mar 22, 2017

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Factorial
Masking
Single (outcomes assessor)
Primary purpose
Other
FDA-regulated device
Yes
Who can join
All sexes, from 55 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Imbio is developing a Smoking Cessation Report (Report) that includes data analysis from a CT lung cancer screening exam. This randomized controlled (RCT) trial will clinically validate the Report's effectiveness at motivating smokers to call a Quitline.

Conditions

  • Smoking Cessation

Interventions

  • Imbio Smoking Cessation ReportDevice

    Research coordinators at the University of Michigan and HealthPartners will be provided access to the research version of LDA via an Imbio website. Following consent and lung screen, research coordinators will manually upload the study participants' images and download a resulting Report. Radiologists have been designated at both sites to review and approve the Report prior to mailing to participants. The Report will include information including the percent of damaged lung volume.

  • Smoking Cessation CounselingBehavioral

    45 minute counseling session with a tobacco treatment specialist.

  • Usual CareOther

    Usual Care for Lung Cancer Screening patients.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Report's Impact on Calling a Quitline NumberTime frame: 3 weeks after intervention.
  2. Report's Impact Making a Quit Attempt Measured Via Follow-up Phone CallTime frame: 3 weeks after intervention
  3. Report's Impact on Calling a Quitline NumberTime frame: 3 months after intervention

3 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Health Partners

    Minneapolis, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.